Dublin, Ireland, November 17th, 2011 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its Medical Imaging division was rated as the top provider of imaging services according to an industry survey conducted by Blue Pyramid Consulting, an affiliate of the Avoca Group.
According to the survey results, ICON Medical Imaging was ranked 1st as the provider most likely to be chosen for future projects. ICON Medical Imaging also received the highest overall ranking for service provider attributes, including operational excellence, technology, scientific/therapeutic expertise, customer responsiveness, value, reputation, financial stability and ability to bundle services. For therapeutic expertise, ICON was voted the leading imaging provider for oncology, cardiovascular and device studies.
Ted Gastineau, President, ICON Medical Imaging, said “We are delighted with the Blue Pyramid survey results and they reflect the dedication of our team in bringing together innovative technology and a customer service model that ensures quality results on every study. Our technology, medical and regulatory expertise have helped clients to accelerate decision-making for many years and we will continue to help them realise the benefits of imaging services across all therapeutic areas and phases of development.”
The Blue Pyramid Consulting survey was developed to gain an insight into the drivers for selecting medical imaging core laboratory providers for clinical research. The online survey was conducted in the first quarter of 2011 and responses were collected from 133 professionals from pharmaceutical, biotech, medical device, not for profit and academic institutions. More detailed results are available from Blue Pyramid Consulting at http://www.bluepyramidconsulting.com/imaging_report.html.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 8,300 employees, operating from 79 locations in 38 countries.
Further information is available at www.iconplc.com
Contact
Yasamin Omoomian
Weber Shandwick
+44 (0)20 7067 0594
